New lozenge aims to ease radiation mouth sores for hours
NCT ID NCT07672236
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tests whether a lozenge called BupiZenge, which contains the long-acting painkiller bupivacaine, can relieve mouth pain from radiation therapy better than the standard lidocaine rinse. About 150 adults with head and neck cancer will be randomly assigned to one of the two treatments. The main goal is to measure pain reduction over three hours after taking the medicine on the last day of radiation.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
bupivacaine lozenge (BupiZenge)
What this could lead to
If it works, this could provide longer-lasting pain relief for mouth sores caused by radiation, reducing the need for strong opioids.
What could go wrong
This is still a trial, so results may not show a clear benefit over lidocaine. Pain relief varies per person, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD NECK CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Helse Bergen HF
Bergen, 5021, Norway
-
Herlev Hospital
Herlev, 2730, Denmark
-
Karolinska University Hospital
Stockholm, SE-17164, Sweden
-
Medical Center - University Of Freiburg
Freiburg im Breisgau, 79106, Germany
-
Næstved Hospital
Næstved, 4700, Denmark
-
Oslo University Hospital HF
Oslo, 0379, Norway
-
Rigshospitalet, Copenhagen University Hospital
Copenhagen, 2100, Denmark
-
University Hospital Cologne (Universitätsklinikum Köln AöR)
Cologne, 50937, Germany
-
University Hospital Frankfurt (AöR)
Frankfurt am Main, 60596, Germany
-
University Hospital Schleswig-Holstein (AöR)
Kiel, 24105, Germany
-
University Hospital Tübingen (AöR)
Tübingen, 72076, Germany